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Background: The fallopian tube epithelium is one of the potential sources of high-grade serous ovarian cancer
(HGSC). The use of estrogen only hormone replacement therapy increases ovarian cancer (OVCA) risk. Despite
estrogen’s influence in OVCA, selective estrogen receptor modulators (SERMs) typically demonstrate only a 20 %
response rate. This low response could be due to a variety of factors including the loss of estrogen receptor
signaling or the role of estrogen in different potential cell types of origin. The response of fallopian tube epithelium
to SERMs is not known, and would be useful when determining therapeutic options for tumors arising from this
cell type, such as HGSC.
Results: Using normal murine derived oviductal epithelial cells (mouse equivalent to the fallopian tube) estrogen
receptor expression was confirmed and interaction with its ligand, estradiol, triggered mRNA and protein induction
of progesterone receptor (PR). The SERMs 4-hydroxytamoxifen, raloxifene and desmethylarzoxifene, functioned as
estrogen receptor antagonists in oviductal cells. Cellular proliferation and migration assays suggested that estradiol
does not significantly impact cellular migration and increased proliferation. Further, using RNAseq, the oviduct
specific transcriptional genes targets of ER when stimulated by estradiol and 4-hydroxytamoxifen signaling were
determined and validated. The RNA-seq revealed enrichment in proliferation, anti-apoptosis, calcium signaling and
steroid signaling processes. Finally, the ER and PR receptor status of a panel of HGSC cell lines was investigated
including Kuramochi, OVSAHO, OVKATE, OVCAR3, and OVCAR4. OVSAHO demonstrated receptor expression and
response, which highlights the need for additional models of ovarian cancer that are estrogen responsive.
Conclusions: Overall, the fallopian tube has specific gene targets of estrogen receptor and demonstrates a tissue
specific response to SERMs consistent with antagonistic action.
Keywords: Estrogen, Fallopian tube epithelium, High-grade serous cancer, Ovarian cancer, Selective estrogen
receptor modulatorsBackground
Ovarian cancer (OVCA) is the most lethal gynecological
malignancy and fifth leading cause of cancer-related
death in women [1]. The fallopian tube epithelium (re-
ferred to as oviduct epithelium in all species except pri-
mates) is one of the likely progenitor cell types for the* Correspondence: joannab@uic.edu
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serous cancer (HGSC) with the alternative cellular
source being the ovarian surface epithelium (OSE) [2].
Morphological, immunological, and gene expression
analysis of HGSC tumors, suggest a close relationship to
fallopian tube epithelium rather than OSE [3, 4]. Precur-
sor lesions, termed the p53 signature, have been identi-
fied in the fimbriated end of the fallopian tube [5]. In
cases of HGSC, these p53 signatures in the fallopian
tube had the same mutation as their correspondinghis article is distributed under the terms of the Creative Commons Attribution 4.0
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termed serous tubal intraepithelial carcinomas (STICs)
have been identified in the fallopian tubes (but not ovar-
ies) of women undergoing risk-reducing salpingo-
oophorectomy, particularly in women with BRCA1/2
mutations [6]. Furthermore, mouse models of HGSC
have been produced by inducing BRCA, PTEN, and p53
mutation in the oviductal epithelium [7].
Risk factors for non-heritable OVCA include null par-
ity, infertility, the number of lifetime ovulations and the
use of estrogen only-hormone replacement therapy [8].
Estrogen is a steroid hormone that functions in multiple
tissues in the body, including the fallopian tube epithe-
lium. While the reproductive role of estrogen in the fal-
lopian tube is to facilitate movement and maturation of
eggs, sperm and fertilized embryos between the ovary
and uterus [9], the function in terms of tumor initiation
and progression is not clear. Estrogen signals in the cell
through three main receptors. Estrogen receptor α (ERα)
and ERβ are ligand activated transcription factors [10].
G protein coupled receptor (GPER) is a membrane
bound factor that signals through a non-genomic mech-
anism [11]. Given the recent findings suggesting that
OVCA is increased by hormone replacement therapy
containing estrogen and the fallopian tube may be the
source of HGSC, the estrogen receptor targets in the fal-
lopian tube should be defined [12].
ERα and a gene target of estrogen signaling, progester-
one receptor (PR), are prognostic biomarkers in OVCA
[13]. ERα is expressed in 80 % of HGSC, but PR is
expressed in only 31 % [13]. Successful treatment of
OVCA with selective estrogen receptor modulators
(SERM) therapy has been limited [14]. SERMs are ER li-
gands that function as either agonists or antagonists in a
cell type specific manner [15]. Given that HGSC may
arise from the fallopian tube, understanding the re-
sponse of normal fallopian tube epithelium to estrogen
and SERMS is important for understanding the implica-
tions of SERM therapy on OVCA risk.
Murine oviduct epithelial (MOE) cells were utilized to
investigate estrogen signaling in a putative HGSC pre-
cursor. MOE cells are estrogen responsive and the
SERMs 4-hydroxytamoxifen (4OHT), raloxifene (RAL)
and desmethylarzoxifene (DMA) antagonize 17-βestradiol
(E2) in this cell type. The MOE specific transcriptional tar-
gets of estrogen signaling were determined by RNAseq. Fi-
nally, the receptor status for ERα, ERβ and PR was
determined in a panel of HGSC cell lines. Our results
highlight the need to consider the E2 response of putative
progenitor cell populations of HGSC to investigate estro-
gen’s role in initiation and progression of OVCA. The oc-
currence and survival rates for OVCA have not improved
in over 40 years emphasizing the necessity for better un-
derstanding and effectively treating or preventing thisdeadly disease. This study demonstrates that estrogen re-
ceptor activates unique oviduct-specific targets that may




MOE and MOSE cells (passages 7-25) were cultured as
previously described [16, 17]. For experiments investi-
gating E2 and SERM response, cells were cultured at
least 48 h in “stripped media” consisting of phenol
red free α-modified Eagle’s medium (Life Technologies,
Carlsbad, CA) supplemented with 10 % v/v charcoal
stripped fetal bovine serum (FBS) (Life Technologies) [18],
1 mg/mL gentamycin (Mediatech, Manassas, VA),
2 mM L-glutamine (Life Technologies), 100 U/mL penicil-
lin and 50 μg/mL streptomycin (Roche, Indianapolis, IN)
prior to treatments. KURAMOCHI (passages 15-25),
OVSAHO (passages 45-60) and OVKATE (passages
45-60) cell lines were purchased from the JCRB Cell
bank and maintained in RPMI1640 (Mediatech) sup-
plemented with 10 % FBS,100 U/mL penicillin and
50 μg/mL streptomycin. OVSAHO were cultured for
48 hours (h) prior to treatment and treated in phenol-red
free RPMI1640 (Life Technologies) supplemented with
10 % charcoal stripped FBS, 100 U/mL penicillin and
50 μg/mL streptomycin. OVCAR4 (passages 15-30) were
acquired from the National Cancer Institute Division of
Cancer Treatment and Diagnosis Tumor Repository
and maintained in the same media as KURAMOCHI
plus 1 % ι-glutamine. SKOV3 (passages 10-30) and
OVCAR3 (passages 3-30) cell lines were acquired from
ATCC (Manassas, VA). SKOV3 were cultured in
McCoy’s 5A supplemented with 2.3 g/L sodium car-
bonate, 10 % FBS, 100 U/mL penicillin and 50 μg/mL
streptomycin. OVCAR3 were maintained in minimum
essential media supplemented with 20 % FBS, 1 % ι-
glutamine, 1 % non-essential amino acids, 1 % sodium
pyruvate, 100 U/mL penicillin and 50 μg/mL strepto-
mycin. Cell lines were authenticated by STR analysis
at DDC Medical (murine) or UIC DNA Services Facil-
ity (human).
Western blotting
Cells were plated at a density of 10-30 × 104 cells per
well in a 6-well dish in stripped media. Twenty-four
hours post plating cells were washed with PBS and the
media was replenished. After another 24 h, cells were
washed with PBS and treated with DMSO (0.1 %) or
compounds for indicated times.
Following treatment, cells were washed with PBS then
harvested on ice in RIPA buffer (50 mM Tris, pH 7.6,
150 mM NaCl, 1 % v/v Triton X-100, 0.1 % w/v sodium
dodecyl sulfate) and frozen at -80 °C. Lysates were
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ples were quantified by BCA (Pierce, Rockford, IL), sepa-
rated by SDS PAGE (8 %) at 100 V for 2.5 h then
transferred for 2 h at 25 V to nitrocellulose (GE Health-
care Bio-Sciences, Pittsburgh, PA). Blots were blocked in
5 % milk TBS-T (Tris Buffered Saline-Tween 20) for 1 h
at room temperature (RT) followed by overnight incuba-
tion at 4 °C in primary antibodies: Anti-ERα (1:300, MC-
20 or 1:200 HC-20, Santa Cruz, Dallas, TX), Anti-PR
(1:500 H-190, Santa Cruz), Anti-actin (1:1000, Sigma-
Aldrich). Following 3 washes in TBS-T, blots were incu-
bated in Anti-rabbit horseradish peroxidase-conjugated
secondary (1:1000, Cell Signaling, Cambridge, MA) for
30 min at RT. After secondary, blots were washed 3X in
TBS-T then bands were imaged using SuperSignal West
Femto Chemiluminescent Substrate (Pierce) on a
FluorChem E Imager (ProteinSimple, Santa Clara, CA).
Densitometry was performed using Protein Simple
software.
qPCR
Cells were treated as described for Western blots, then
harvested in 500 μL of Trizol Reagent (Life Technolo-
gies) and frozen at -80 until processed according to
manufacturer’s protocol. Purified RNA was treated with
DNAseI (New England Biolabs, Ipswich, MA) for
10 min, followed by heat inactivation. 1 μg of purified
RNA was reverse transcribed using Revertaid Reverse
Transcriptase (Thermo Fisher Scientific, Waltham, MA)
in the presence of Ribolock RNAse Inhibitor (Thermo
Fisher Scientific). Expression was monitored using Fas-
tstart Universal Sybr Green (Rox) (Roche) using proto-
col: 10 min at 94 °C, 40 cycles of 10 sec at 94 °C, 30 sec
at 60 °C followed by a melt curve. Primers listed in Add-
itional file 1: Table S1.
Immunofluorescence
MOE cells were cultured in charcoal stripped media for
72 h and then plated (50,000 per well) onto Millicell EZ
slides (Millipore, Billerica, MA). The next day the cells
were fixed with 4 % paraformaldehyde and probed with
primary antibody against estrogen receptor α (1:200,
MC-20, Santa Cruz) with 10 % goat serum. Slides
washed and probed with secondary antibody (AlexaFluro
594 A11037, Life Technologies) before mounting with
DAPI containing mounting media (H-1500, Vector La-
boratories, Burlingame, CA). Images were captured with
a Nikon Eclipse E600 microscope at 40x.
Proliferation assay
Cells were cultured in stripped media for 72 h followed
by passaging and plating of 1,000 cells/well in a 96 well
plate. Twenty-four hours post plating, cells were treated
with solvent or compounds for 72 h then fixed with20 % w/v Trichloroacetic acid for 24 h at 4 °C and proc-
essed for sulforhodamine B colorimetric assay as de-
scribed [19]. Absorbance at 505 nm was measured using
a BioTek Synergy MX microplate reader (BioTek,
Winooski, VT).Wound healing assay
Cells were cultured for 72 h as described in the prolifer-
ation assay, followed by passaging and plating of 6×104
per well in a 24 well plate. Twenty-four hours post plat-
ing a pipette tip induced a scratch across the monolayer
of cells. Images of the wound were taken at time zero
and 24 h post scratch. The percent closure of the wound
was calculated as the area of the scratch at 24 h post
scratch divided by the area of the scratch at time zero
using ImageJ (National Institutes of Health).Luciferase assay
SKOV3 cells were trypsinized and plated in 24-well plate
(3.5 × 104 cells/ well) in stripped media. Incubation of
cells with pERE-luciferase plasmid (100 ng/well) [20],
RSV-β-galactosidase (100 ng/well, [21], and TransIT LT1
transfection reagent (1 μL per well, Mirus Bio, Madison,
WI) was performed overnight in fresh media then treated
for 24 h. Luciferase production and β-galactosidase activ-
ity (for transfection normalization) were measured as
described previously [21].RNAseq library construction and sequencing
Cells were treated as described in qPCR assay, followed
by RNA isolation using Qiagen Qiashredder column, on
column DNAse treatment and Qiagen RNAeasy spin
columns (Qiagen, Valencia, CA). Library construction
and sequencing were performed at the Genomics Core
facility at the University of Chicago. RNA quality and
quantity were determined with the Agilent Bioanalyzer
2100, with RNA integrity numbers (RIN) of 10 and
quantities of 100 ng or more per sample. Samples were
enriched for mRNA using oligo-dT columns. Directional
50 bp single-end mRNA libraries were prepared using
Illumina TruSeq mRNA Sample Preparation Kits per
manufacturer’s instructions. Briefly, polyadenylated
mRNAs were captured from total RNA using oligo-dT
selection. Next, samples were converted to cDNA by
reverse transcription, and each sample was ligated to
Illumina sequencing adapters containing unique barcode
sequences. Barcoded samples were then amplified by
PCR and the resulting cDNA libraries quantified using
qPCR. Finally, equimolar concentrations of each cDNA
library were pooled and sequenced on the Illumina
HiSeq2500.
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The quality of DNA reads, in fastq format, was evaluated
using FastQC. Adapters were removed and reads of poor
quality filtered. The data was processed largely following
the procedure described in [22]. Briefly, reads were
aligned to the Mus musculus genome (mm10) using
TopHat (v2.0.8b). Subsequently, aligned reads, in con-
junction with a gene annotation file for mm10 obtained
from the UCSC website, were used to determine the ex-
pression of known genes using Cufflinks (v2.1.1). Indi-
vidual transcript files generated by Cufflinks for each
sample were merged into a single gene annotation file,
which was then used to perform a differential expression
analysis with the Cufflinks routine, cuffdiff. Differential
expression was determined by cuffdiff using the proced-
ure described in Trapnell et al [22], using an FDR cutoff
value of 0.05. Results of the differential expression ana-
lysis were processed with cummeRbund. Differentially
expressed genes were separated into upregulated and
downregulated lists. A pathway analysis was performed
on both gene lists using GeneCoDis [23–25] to identify
pathways enriched with genes that were upregulated and
downregulated.
Statistical analysis
Data shown are represented as the mean of at least three
experiments, with errors bars representing the standard
error. Statistical analysis was conducted with GraphPad
Prism (GraphPad, La Jolla, CA) using one-way ANOVA
with a Tukey’s post hoc test.
Results
Putative OVCA progenitor cell type estrogen responsive
The fallopian tube (oviduct in the mouse) epithelium is
likely one of the sources of HGSC. To investigate the
role of estrogen signaling in this precursor cell type of
HGSC, we evaluated the response of murine oviductal
epithelium (MOE) cells derived from CD1 and FVB
murine backgrounds subjected to 17-beta-estradiol (E2)
treatment (Fig. 1a, b). CD1 MOE cells are a polyclonal
cell line consisting of both secretory and ciliated ovi-
ductal epithelial cells [16]. The FVB MOE cells are
monoclonal, comprised exclusively of secretory oviductal
epithelial cells [17]. The disappearance of ERα via prote-
asome–mediated proteolysis [26], and upregulation of
the canonical ER regulated target progesterone receptor
(PRA and PRB, two isoforms encoded by the Pgr gene)
were monitored for E2 responsiveness via Western blot
analysis. Immunofluorescence revealed that 100 % of
FVB MOE cells expressed ERα (Fig. 1e). MOE cell lines
demonstrated robust E2 responsiveness for these
endpoints.
HGSC is a heterogeneous disease, the only common
alteration (<96 % of cases) being a mutation in the Tp53gene [27]. Intriguingly, FVB MOE cells stably transfected
with a plasmid encoding the human Tp53 gene mutated
at R273H [17] expressed elevated protein levels of both
ERα and PRA/PRB (Fig. 1b), although the transcriptional
strength of PR induction by E2 was not significantly
different than observed in wildtype MOE FVB cells
(Additional file 2: Figure S1a-c).
A human fallopian tube secretory epithelial cell
(FTSEC) line [28] did not express detectable ERα and
PR, precluding study of E2 responsiveness in human
cells (Fig. 1c), although transient transfection of a plas-
mid encoding ERα did recover the ability for E2 to in-
duce transcription of Pgr (data not shown). Continuous
culturing of the CD1 MOE cell line resulted in a de-
crease of the receptors (Fig. 1d) suggesting growth on
plastic is capable of inducing receptor loss. These results
were similar to a baboon FTSEC that also lost receptor
in culture that could be reactivated [20].
The E2 responsiveness of the classically studied OVCA
precursor, the ovarian surface epithelium (OSE) was also
investigated. A murine ovarian surface epithelium
(MOSE) cell line from the FVB background [16],
expressed much less ERα and PRA/PRB compared to
the MOE cell lines, and further PRA/PRB levels were
not altered by E2 treatment (Fig. 1b). OSE are known to
express the receptors in vivo [29], once again indicating
culturing on tissue culture plastic could lead to receptor
depletion. Attempts to enhance receptor expression and
E2 responsiveness of MOSE cells using an HDAC in-
hibitor (HD13) [30] or the demethyltransferase inhibitor,
5-azacytidine were unsuccessful (Additional file 2: Figure
S1d and data not shown).
SERMs antagonize E2 in MOE
Women at high risk for breast cancer and OVCA, hav-
ing a mutation in either BRCA1 or BRCA2 genes, may
prophylactically take selective estrogen receptor modula-
tors (SERMs), such as 4-hydroxytamoxifen (4OHT), to
decrease their risk of developing breast cancer [31].
SERM action as an ER agonist or antagonist is cell type
specific and the effect on ER and the response of the fal-
lopian tube epithelium in terms of cancer biology to
SERMs is not well documented. MOE cells were used to
elucidate whether the SERMs 4OHT, raloxifene (RAL)
and desmethylarzoxifene (DMA), function as ER antago-
nists or agonists. QPCR analysis of the genes Pgr and
Greb1, revealed significant (p < 0.001) induction in re-
sponse to E2 in both CD1 and FVB MOE cells (Fig. 2a, b
and Additional file 3: Figure S2a,b). All SERMs tested
did not significantly activate Pgr or Greb1 compared to
the DMSO but did significantly (p < 0.001) antagonize E2
dependent induction in both MOE cell lines (Fig. 2a, b
and Additional file 3: Figure S2a,b). Western blot ana-
lysis of CD1 MOE treated with E2 and SERMs revealed
Fig. 1 Receptor status and estrogen responsiveness monitored by Western blot analysis. a Analysis of ERα and PR expression in response to 24 h
17β-estradiol (1nM, E2) treatment in CD1 MOE cells or (b) FVB MOE and MOSE cells. c Western blot analysis of human fallopian tube secretory epithelial
cells (FTSEC) and receptor positive MCF7 breast cancer cells. d Receptor protein levels of early passage (P14) and late passage (P85) Cd1 MOE cells.
e Immunofluorescence in FVB MOE cells for ERα and DAPI counterstain. Scale bar = 20 μm
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ERα in response to E2 treatment (Fig. 2c, d, e). These
findings indicate that the SERMs antagonize E2 in ovi-
duct epithelial cells.
E2 increases the growth rate in a subset of ER positive
OVCA cell lines [32, 33]. The reported functional re-
sponse of fallopian tube epithelial cells to estrogen sig-
naling involves triggering the differentiation of epithelial
cells, protein secretion, and regulation of cilia beating
[34]. In vivo proliferation rates have not been reported
to change due to ovulation, which has high levels of es-
trogen in the follicular phase of the cycle. To evaluate
the functional response of MOE cells to E2 and SERMs,
a proliferation assay was employed. Following 72-hour
treatment, a small but significant (p < 0.05) proliferation
increase was observed in the presence of E2 but notSERMs in CD1 MOE cells (Fig. 3a). This E2 dependent
proliferative increase was blocked by all the SERMs
tested. No E2 dependent growth increase was observed
in the FVB MOEs suggesting a strain specific E2 respon-
siveness (Additional file 3: Figure S2b).
To determine if E2 and SERMs alters the migration of
MOE cells, a wound-healing assay was utilized. No dif-
ference in migration was observed for either MOE cell
line (Fig. 3b and Additional file 3: Figure S2c), suggesting
E2 does not enhance the migration of normal oviductal
epithelial cells.
RNAseq of MOE cells
The particular set of genes regulated by E2 is cell
type specific [15]. A number of E2-regulated genes in
breast cancer cell lines were not altered by E2
Fig. 2 SERMs antagonize E2 in CD1 MOE. a, b qPCR analysis of (a) Pgr and (b) Greb1 induction in response to 48 h hormone starvation and
24 h treatment with DMSO, 1 nM E2 or 100 nM SERMs. “a” indicates significant difference compared to all treatments (p < 0.001) and “b”
is significantly different than DMSO control treatment (p < 0.01). c Western blot analysis of CD1 MOE treated for 24 h with 1 nM E2 and
100 nM SERMs and the combination. d, e Densitometry of ERα and PRA bands relative to solvent treated cells normalized to actin. ERα is
significantly lower in E2, RAL and DMA treated cells, while 4OHT does not result in ERα degradation. PR is significantly upregulated in E2
treated cells compared to all conditions. Significance determined by one-way ANOVA followed by Tukey’s post hoc test where * indicates
p < 0.05, ** indicates p < 0.01, *** indicates p < 0.001
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file 3: Figure S2e) [35]. To identify E2 regulated genes in
the oviduct epithelia, RNAseq was performed on FVB
MOE cells treated for 24 h with solvent (DMSO), 1 nM E2
or 100 nM 4OHT in triplicate. The FVB MOE cell line
was utilized for two reasons. First, HGSC is thought to
arise from the secretory cells of the fallopian tube. The
FVB MOE line is a monoclonal cell line of exclusively
secretory cells [17]. Second, the cell model was
chosen instead of primary oviduct culture since pri-
mary cells would have contaminating ciliated and
underlying stromal cells that could confound the
results [36]. Over 438 million reads between the 9
samples (between 40-60 million per sample) weresequenced using Illumina HiSeq2500 platform (Additional
file 1: Table S2).
Analysis of the dataset identified 314 gene targets dif-
ferentially expressed (287 upregulated and 28 downregu-
lated, FDR adjusted p-value < 0.05) in response to E2
compared to DMSO treated MOE cells. The top 15
genes significantly up and down regulated are listed in
Table 1 and 2, respectively. Few genes were shown to be
differentially expressed between DMSO and 4OHT
(Additional file 1: Table S3 and Additional file 1: Table
S4) and only 4 were 4OHT specific, further suggesting
that 4OHT functions as an ER antagonist in this cell
type. 274 genes targets were differentially expressed be-
tween E2 and 4OHT treated MOE cells. Figure 4a
Fig. 3 Functional response of CD1 MOE to E2 signaling (a) Relative
growth of CD1 MOE following 72-hour hormone starvation and 72-hour
treatment with DMSO, 1 nM E2, 100 nM SERMS and the combination as
monitored by SRB assay. * indicates significant difference from all other
treatments (p< 0.05). b Relative migration of CD1 MOE cells following
72-hour hormone starvation and 24-hour treatment (wound initiated at
time of treatment) with DMSO, 1 nM E2 or 100 nM SERMs
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Gene Description
Bpifc BPI fold containing family C
Gbp8 Guanylate-binding protein 8
Csf2 Colony stimulating factor 2 (granulocyte-macrophage)
Cldn10 Claudin 10
Ptprz1 Protein tyrosine phosphatase, receptor type Z, polypep
Dhrs9 Dehydrogenase/reductase (SDR family) member 9
Oit1 Oncoprotein induced transcript 1
Wasf3 WAS protein family, member 3
Bcas1 Breast carcinoma amplified sequence 1
Pgr Progesterone receptor
Dcn Decorin
F5 Coagulation factor V
Krtap1-5 Keratin associated protein 1-5
Padi2 Peptidyl arginine deiminase, type II
Padi1 Peptidyl arginine deiminase, type Iillustrates the number of regulated genes in common be-
tween each condition, highlighting a large overlap in
genes differentially regulated by E2 compared to DMSO
and 4OHT. A subset of genes, Csf2, Dhrs9, and Dcn
were validated for response to E2 and 4OHT by qPCR
(Fig. 4b-d).
GO analysis of the upregulated genes in response to
E2 identified a number of biological processes. The heat
map shown in Fig. 4e reflect changes in expression be-
tween DMSO versus E2 or 4OHT for the two most
enriched biological processes. Regulation of proliferation
was the largest group identified. Regulation of apoptosis
was the second highest group enriched. Other signifi-
cantly enriched processes include response to steroid
hormone stimulus, mammary gland epithelium develop-
ment and calcium ion homeostasis.
OVCA cell line receptor status
Estrogen only hormone replacement therapy and the
number of lifetime ovulations are associated with
OVCA [8] . The SKOV3 cell line is the most cited
OVCA cell line [37]. Previous reports indicate that
SKOV3 are not growth responsive to E2 due to expres-
sion of a truncated ERα [38]. While SKOV3 were re-
sponsive to E2 by a reporter assay containing an ERE-
binding element fused to a luciferase gene (Fig. 5a),
they were not at the endogenously regulated PGR gene
by either qPCR or Western blot analysis (Figs. 5b, c).
Another commonly used E2-responsive cell line in the
OVCA literature, BG1, was reported to proliferate in
response to estrogen, although a subset of studies using
this cell line has subsequently been identified as MCF7
breast cancer cells [39]. Currently, neither cell type areMOE cells
















Table 2 Top 15 down-regulated genes between DMSO and E2 treated MOE cells
Gene Description Log2 fold change FDR adjusted p-value
H19 H19, imprinted maternally expressed transcript -1.65 0.02
Mep1a Meprin 1 alpha -1.48 0.03
Rgs8 Regulator of G-protein signaling 8 -1.35 0.05
Hhip Hedgehog-interacting protein -1.26 0.01
G6pc2 Glucose-6-phosphatase, catalytic, 2 -1.14 0.01
Adamts16 A disintegrin-like and metallopeptidase (reprolysin type) with
thrombospondin type 1 motif, 16
-1.09 0.01
Apln Apelin -1.05 0.01
Cyp26a1 Cytochrome P450, family 26, subfamily a, polypeptide 1 -0.88 0.02
Upk3b Uroplakin 3B -0.83 0.05
Aqp1 Aquaporin 1 -0.70 0.03
Nup210 Nucleoporin 210 -0.65 0.05
Tgfbr3 Transforming growth factor, beta receptor III -0.64 0.02
I830012O16 Rik, Ifit3 RIKEN cDNA I830012O16 gene -0.63 0.01
Havcr1 Hepatitis A virus cellular receptor 1 -0.62 0.01
Pdk4 Pyruvate dehydrogenase kinase, isoenzyme 4 -0.62 0.01
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velop from fallopian tube cells [37] and highlight the
need to explore additional cell models.
We analyzed a number of representative and commer-
cially available HGSC lines for the presence of the ster-
oid hormone receptors ERα, PR, and ERβ. Molecular
profiling of these cell lines predict OVSAHO, Kuramochi,
OVCAR4 and OVKATE are likely, while OVCAR3 is pos-
sibly and SKOV3 is unlikely to be HGSC [37]. All OVCA
cell lines tested expressed much less or no ERα and PR
compared to the receptor positive breast cancer cell
line MCF7 by both Western blot and RNA analyses
(Fig. 5d-e). ERβ status was monitored for all samples by
qPCR revealing minimally detectable amounts mRNA
(Fig. 5e, a cell line expressing a plasmid encoding
ERβ was used to validate the primers). The dearth of
ER and PR receptors in OVCA cell lines is in con-
trast to the 60 % of ER positive tumors [13] and
makes investigation into the role of estrogen in
OVCA challenging.
Despite low levels of ERα and PR in the OVCA cell
lines, one HGSC cell line, OVSAHO, which expressed
ERα and PR was tested for E2 responsiveness.
OVSAHO proliferation was significantly increased by
E2, but not SERMs, following a 7 day treatment, and
the SERMs antagonized E2 dependent growth (Fig. 5f ).
Following 24-hour treatment, a mild albeit not signifi-
cant induction was observed at the PGR gene in re-
sponse to E2, 4OHT and E2 plus 4OHT (Fig. 5g).
Therefore, despite the lower levels of receptors com-
pared to MCF7 breast cancer cells, OVSAHO are an
estrogen responsive cell model.Discussion
The epithelium of the fallopian tube is considered to be
one of the origins of HGSC and estrogen replacement
therapy impacts the risk of OVCA. This study character-
ized the agonist/antagonist function of SERMs in a nor-
mal murine model of fallopian tube epithelium,
identified the genes regulated by estrogen signaling in
this cell type to shed light on the subset of genes regu-
lated by E2 in this cell type, and determined the E2
responsiveness of a panel of HGSC cell lines.SERMS antagonize E2 in MOE cells
Tamoxifen is a common treatment for receptor positive
breast cancer, as well as given prophylactically for
women at high risk for developing breast cancer [31].
Given the risk associated with Tamoxifen for the uterus,
the response of Tamoxifen and other SERMs in the fallo-
pian tube epithelium is highly important for clarifying
the risks of using these drugs in women with intact fallo-
pian tubes. Responses such as proliferation or migration
has not been well documented in fallopian tube epithe-
lium as compared to the response in the breast or uter-
ine tissue, traditional hormone responsive tumor types
[20]. Reports from our lab indicate that estrogen did not
proliferate oviductal epithelium in FVB strains, or in
organotypic cultures of the mouse, baboon, or human
[20, 40]. Long term (at least 4 years) Tamoxifen treat-
ment of women with breast cancer has been reported to
increase tubal dysplasia [41]. The anti-estrogen effect re-
ported here on isolated epithelial cell lines suggests the
dysplastic effect of tamoxifen may not be due to
Fig. 4 RNAseq analysis of FVB MOE secretory cells treated with E2 and 4OHT. a Venn diagram of overlap of regulated genes between
conditions. b-d qPCR analysis of genes identified as E2 regulated by RNAseq. Significant difference from DMSO control represented by ***
(p < 0.001) and * (p < 0.05) for b) Csf2. c) Dhrs9. d) Dcn. e Heat map of genes significantly regulated by E2 clustered by GO analysis for biological
processes. Log2 Fold change shown for DMSO versus E2 and DMSO versus 4OHT
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transcriptional effects, such as DNA damage [42].
RNAseq identifies targets of E2 signaling in MOE cells
Many E2 regulated genes in other normal and cancer cell
types were also regulated in MOE cells including Pgr,
Greb1, Csf2, and Dhrs9 [43, 44], while other E2 regulated
genes in MCF7 cells were not regulated (Nrip1) [35] or
even expressed (Tff1) in MOE cells [45]. Interestingly, in
contrast to MCF7 [45], the majority of differentiallyexpressed genes were upregulated in MOE cells at the
time point (24 h) probed. Table 1 and 2 lists the most
highly regulated genes in response to E2 in MOE cells,
some of which are relatively uncharacterized. BPI fold
containing family C gene (Bpifc), involved in lipid bind-
ing [46], demonstrated the largest induction in response
to E2. One gene specifically upregulated by 4OHT was
the RNA component of mitochondrial processing endo-
nuclease (Rmrp), reported to be upregulated in 4OHT
resistant as compared to 4OHT sensitive breast cancer
Fig. 5 Estrogen signaling in ovarian cancer cell lines. a Luciferase reporter assay of SKOV3 cells transfected, hormone starved for 48 h and
treated for 24 h with 1 nM E2 and or 100 nM 4OHT. ERE-luciferase activity was normalized for transfection efficiency to the betagal control signal.
Significant difference from DMSO control denoted by * (p < 0.05). b qPCR analysis of Pgr mRNA levels in SKOV3 as described in a. c Western blot
analysis of ERα and PR levels in SKOV3 cells as described in (d) Western blot analysis of ERα and PR status of a panel of HGSC cell lines with positive
control MCF7 cells and the commonly used undifferentiated OVCA cell line SKOV3. OVSAHO, OVKATE and SKOV3 reveal low ERα expression, while
none of the cell lines expressed detectable PR expression compared to MCF7. e-g qPCR analysis of Esr1, Pgr and Esr2 mRNA levels in HGSC cell lines.
h Relative growth of OVSAHO cells treated with 1 nM E2 or 100 nM SERMs for 7 days. Cells were grown as described in Fig. 3a except media
was replenished after 72 h. Significant difference from untreated and DMSO treated cells represented by “a” (p < 0.01) and significant difference from
SERM treated cells represented by “b” (p < 0.05) i) qPCR analysis of Pgr induction in response to E2 and 4OHT treatment in OVSAHO cells
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cells included regulation of proliferation and apoptosis,
response to hormone stimulus and calcium ion homeo-
stasis. The RNAseq analysis identified genes responsible
for both positive and negative regulation of proliferation,
which may reconcile the lack of significant proliferative
increase in the FVB MOE background. In the fallopian
tube, calcium is required for sperm capacitation [48] and
cilia beating [49], therefore E2 may regulate calciumlevels in the fallopian tube as part of reproductive
biology.
Comparison of the MOE E2 responsive genes and The
Cancer Genome Atlas of ovarian cancer tumors identi-
fied a number of genes with significance in OVCA in
common between the two groups [27, 50, 51]. For ex-
ample, E2 increased expression of the cyclin dependent
kinase 2 (Ccnd2) gene, which is altered (via amplification
or mRNA upregulation) in 12 % of ovarian tumors, and
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Jak2, and Kit were also upregulated in response to E2
and altered in 12 % and 8 % of ovarian tumors, respect-
ively. The St3gal1 gene, encoding a glycosyltransferase,
was upregulated by E2 and altered (mostly amplified or
showing mRNA upregulation) in 30 % of ovarian tu-
mors. The significance of ST3Gal1 in OVCA is un-
known, but has been linked to colon cancer [53]. Cyclin
dependent kinase 1 (Ccnd1) was downregulated in re-
sponse to E2 and altered in 8 % of ovarian tumors. Inter-
estingly, CCND1 is overexpressed in cisplatin resistant
testicular cancer and OVCA [54]. The overlap of genes
regulated by E2 in MOE cells and alteration in OVCA
provides a number of potential new targets for further
investigation of E2 regulation in OVCA.Need for better E2 responsive models of HGSC
The most frequently used estrogen responsive OVCA
cell lines are not ideal models of HGSC including
SKOV3 and the NIEHs BG1 cells [38, 39]. Two other es-
trogen responsive OVCA cell lines, PEO1 and PEO4,
have recently been reported as HGSC [55]. These cell
lines proliferate in response to E2 in culture and xeno-
grafts and E2 increases risk of distant metastases [32, 33].
The HGSC cell lines investigated in this study express
much less ER and PR receptors compared to the estrogen
responsive MCF7. Nevertheless, the likely HGSC cell line
OVSAHO proliferates in response to E2, but not SERMs.
Further validation of other/more estrogen responsive
HGSC cell lines is desperately needed to aid in under-
standing the role of estrogen in OVCA and whether ER
expressing HGSC would respond to anti-estrogen therapy.
By studying how the cancers and different progenitors,
such as the oviductal or OSE, respond to estrogen may aid
in the use of SERMs in tumors that express ER or help to
uncover if long-term use of Tamoxifen could enhance
dysplastic lesions in the fallopian tube.Conclusion
This study shows that the fallopian tube epithelia re-
spond to E2 stimulation by regulating expression of a
tissue-specific set of target genes. All SERMs tested
inhibited E2-stimulated responses, showing SERMs are
antagonistic action in the fallopian tube. Thus direct ef-
fects of E2 on the fallopian tube epithelium may play a
role in the development of ovarian cancer.Ethics approval
Not Applicable.Consent for publication
Not applicable.Availability of data and material
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read counts. Table S3. Genes significantly up-regulated by 4OHT in MOE
cells. Table S4. Genes significantly down-regulated by 4OHT in MOE cells.
(DOC 78 kb)
Additional file 2: Figure S1. E2 response in putative OVCA precursor
cell types. a, b) Densitometry of ERα and PRA protein levels in response
to 1 nM E2 treatment (relative to solvent control and normalized to actin)
of FVB MOE and FVB MOEp53R273H cells. c) qPCR analysis of Pgr induction
in response to 24 h treatment with 1 nM E2 in FVB MOE and FVB
MOEp53R273H cells. d) FVB MOSE cells treated with an HDAC inhibitor
(HD13) does not upregulate ERα or recover E2 responsiveness. Significant
difference relative to DMSO control denoted by * (p < 0.05), ** (p < 0.01),
and *** (p < 0.001). (TIF 150 kb)
Additional file 3: Figure S2. FVB MOE response to E2 and SERMs. a, b)
qPCR analysis of (a) Pgr and (b) Greb1 induction in response to 48 h
hormone starvation and 24 h treatment with solvent, 1 nM E2 or 100 nM
SERMs. “a” indicates significant difference compared to all treatments. c)
Relative growth of FVB MOE following 72-hour hormone starvation and
72-hour treatment with solvent, 1 nM E2, 100 nM SERMs and the combination
as monitored by SRB assay. d) Relative migration of FVB MOE cells following
72-hour hormone starvation and 24-hour treatment with solvent, 1 nM E2 or
100 nM SERMs. Wound initiated at time of treatment. e) qPCR analysis of Nrip1
expression levels in CD1 and FVB MOE cells in response to 24 h treatment
with DMSO or 1 nM E2. (TIF 615 kb)
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